AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

Delisting risk

GOVX · NASDAQ · Biotechnology

GeoVax Labs

Clinical developer of an mpox/smallpox vaccine and gene-directed therapy for head-and-neck cancer.

$0.6400

After-hours close−0.08 (−11.22%)

At close$0.7209(+0.54%)

Something off on this page? Send us feedback.

Profile

GeoVax Labs, Inc.GOVXHealth Care

Develops an unapproved mpox and smallpox vaccine candidate and a gene-therapy candidate for head-and-neck cancer, relying on external clinical and manufacturing partners, licensed technologies, and equity-linked financing rather than product sales.

Develops GEO-MVA, an MVA vaccine candidate for mpox and smallpox, and Gedeptin, a gene-directed enzyme/prodrug therapy for head-and-neck cancer. Neither program is approved or commercial, and no product-sale revenue has been generated.

Operates as a biotechnology research-and-development organization with a small internal workforce, using CROs, CMOs, licensors, and testing vendors to execute clinical development and manufacture supplies. GEO-MVA uses the MVA platform, while Gedeptin uses a separate adenoviral-vector platform.

Seeks to commercialize approved candidates internally or through licensing, partnerships, and government or international procurement. Progress depends on further clinical work, regulatory authorization, manufacturing scale-up, licensed intellectual property, third-party execution, and equity-linked financing.

Company facts

CEODavid A. Dodd

ListedSep 25, 2020

ExchangeNASDAQ

HeadquartersSmyrna, GA

CountryUnited States

Employees19

CIK0000832489

ISINUS3736787058

Key statistics

Market cap$5.3M

EPS (ttm)−$13.89

P/E (ttm)−0.0519

ROE-743.7%

P/B1.87

P/S0.00

Dividend yield—

Beta1.86vs XLV −0.28

Year to date −86.1% · Average volume (30d) 848.8K

Analysts

Price target, next 12 months$100.00+13,788.9%Median of 7 analysts · vs the Aug 28 close

ConsensusBuy6 of 7 analysts rate it buy or better

Ratings

Strong buyBuyHoldSellStrong sell

Target range

Last close $0.7200

High$100.00+13,788.9%

Median$100.00+13,788.9%

Low$100.00+13,788.9%

12 months agoNowIn 12 months

Latest analyst notes

Date	Firm	Action	Prior rating	Rating
Feb 19, 2026	D. Boral Capital	Downgrade	Buy	Hold

Earnings

EPS

Estimate−$1.03

ReportedDue Nov 12, 2026

Revenue

Estimate—

ReportedDue Nov 12, 2026

History

Report date	EPS est	EPS	Surprise	Revenue est	Revenue	Surprise	Next session
Jul 27, 2026Q2 FY26	−$2.16	−$0.97	+55.1%	—	—	—	−4.37%
May 14, 2026Q1 FY26	−$1.60	−$2.62	−63.7%	—	—	—	−2.38%
Apr 2, 2026Q4 FY25	−$4.71	−$2.29	+51.3%	$1.0M	—	—	−6.02%
Nov 13, 2025Q3 FY25	−$6.00	−$7.75	−29.2%	—	—	—	−3.84%

View details

Financial highlights

	Q1 FY25	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26
Revenue	$1.6M	$852.3K	$0	$0	$0	$0
Gross profit	−$3.7M	−$3.9M	−$5.0M	$33.7K	−$3.9M	−$12.1K
Operating income	−$5.4M	−$5.4M	−$6.4M	−$4.4M	−$5.3M	−$4.4M
Net income	−$5.4M	−$5.4M	−$6.3M	−$4.4M	−$5.3M	−$4.4M
Diluted EPS	−$11.25	−$8.75	−$7.75	−$2.55	−$2.62	−$0.97
Gross margin	-227.1%	-454.9%	—	—	—	—
Operating margin	-330.2%	-635.8%	—	—	—	—

Fiscal years (4-quarter sums)FY21 $385.5K · FY22 $81.5K · FY23 $0 · FY24 $4.0M · FY25 $2.5M

Balance sheet, Jun 30, 2026Cash & short-term investments $3.1M · Total debt $323.1K · Total assets $4.6M · Shareholders' equity $1.8M

Dividends

No dividends on record.

Ownership

Institutions 4.52%333.4K sharesInsiders 0.04%2.9K sharesOther 95.44%7.03M shares

Shares outstanding 7.37M · Float 7.19M · 97.6% free float

A split settled inside the quarter being compared, so quarter-on-quarter change is not shown.

Top shareholders13F · 13D/G · Form 4

Holder	Shares	% outstanding	Form	Filed
Ayrton Capital LLC	4.81M	9.99%	13G	Feb 11, 2026
Jane Street Group, LLC	292.8K	5.60%	13G	Jun 9, 2026
Armistice Capital, LLC	291.2K	9.99%	13G	May 15, 2026
Mitchell P. Kopin	233.3K	9.99%	13G	May 13, 2026
Geode Capital Management, LLC	36.1K	0.49%	13F	May 15, 2026

Insider tradesForm 4

No open-market trades in the last 12 months.